Biotricity, Inc.
BTCY · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.03 | 0.03 | -0.07 |
| FCF Yield | -32.52% | -52.06% | -56.07% | -14.73% |
| EV / EBITDA | -10.28 | -4.04 | -2.68 | -5.74 |
| Quality | ||||
| ROIC | 100.16% | 189.35% | -3,351.02% | -123.41% |
| Gross Margin | 76.61% | 69.27% | 56.46% | 59.74% |
| Cash Conversion Ratio | 0.28 | 0.47 | 0.73 | 0.52 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.68% | 16.39% | 41.74% | 75.40% |
| Free Cash Flow Growth | 64.44% | 50.59% | 10.83% | -37.11% |
| Safety | ||||
| Net Debt / EBITDA | -8.01 | -2.60 | -1.18 | -0.18 |
| Interest Coverage | -0.47 | -1.70 | -5.97 | -1.58 |
| Efficiency | ||||
| Inventory Turnover | 2.07 | 1.97 | 1.80 | 3.65 |
| Cash Conversion Cycle | -272.80 | -274.50 | -49.15 | 58.23 |